Delivery Order SPE2DB24D9238-SPE2DB25FDRBF
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $17,122.20 by the Defense Logistics Agency on August 1, 2025, for the supply of Xolair 150 mg/ml auto-injectors. The award is issued under a firm fixed-price contract structure with an ultimate completion date of August 22, 2025, and represents no set-aside designation. This delivery order draws from DMS Pharmaceutical Group's larger...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order by the Defense Logistics Agency (DLA) on August 20, 2025, for the supply of Xolair 300 mg/2 ml auto-injector vials. The contract has a ceiling value of $85,611.50 with an ultimate completion date of September 11, 2025, and carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's existing...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a delivery order by the Defense Logistics Agency (DLA) for Xolair 75 mg/0.5 mL auto-injector vials. The contract, valued at $1,277.01 with a firm fixed-price structure, is scheduled for completion by September 24, 2025. This delivery order was awarded without set-aside designation on September 3, 2025, and represents a continuation of DMS Pharmaceutical Group's...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a firm fixed-price delivery order valued at $1,712.23 by the Defense Logistics Agency (DLA) for the supply of Xolair 300 mg/2 ml auto-injector vials. The delivery order, issued on September 3, 2025, with an ultimate completion date of September 24, 2025, carries no set-aside designation. This award is issued under DMS Pharmaceutical Group's existing single-award...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a delivery order by the Defense Logistics Agency (DLA) for Xolair 300 mg/2 ml auto-injector prefilled syringes. The contract, valued at $6,848.92 with a firm fixed-price structure, was awarded on August 13, 2025, with an ultimate completion date of September 4, 2025. This delivery order carries no set-aside designation and will be performed at the company's Park...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $37,137.60 by the Defense Logistics Agency (DLA) on August 21, 2025. The delivery order, which carries no set-aside designation, is for Xolair 150 mg/ml syringes with an ultimate completion date of September 12, 2025. This award represents a single delivery order issued under DMS Pharmaceutical Group's larger Indefinite...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a delivery order valued at approximately $142,000 by the Defense Logistics Agency (DLA) for XOLAIR 150 mg/ml syringes. The contract is firm fixed-price with an ultimate completion date of September 16, 2025, and was awarded on August 25, 2025, without set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $28.3K by the Defense Logistics Agency's Medical Supply Chain on August 27, 2025, for the supply of Xolair 300 mg/2 ml auto-injector units. This firm fixed-price delivery order is scheduled for completion by September 18, 2025, with no set-aside designation applied. The award represents a discrete fulfillment under DMS Pharmaceutical...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $3,094.80 by the Defense Logistics Agency on August 27, 2025, for the supply of Xolair 150 mg/ml syringes. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of September 18, 2025, and carries no set-aside designation. This award is issued under DMS Pharmaceutical Group's larger single-award...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $4,642.20 by the Defense Logistics Agency (DLA) on September 4, 2025. The delivery order is for Xolair 150 mg/ml syringes, with an ultimate completion date of September 25, 2025. This award carries no set-aside designation, allowing the vendor to compete on equal footing in the federal procurement marketplace. The place of...
- SPE2DB24D9238Indefinite Delivery Contract
- SPE2DB24D9238-SPE2DB25FDRBFDelivery Order
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a firm fixed-price delivery order valued at $1,712.22 by the Defense Logistics Agency (DLA) for the supply of Xolair 150 mg/ml auto-injectors. The delivery order, issued on September 12, 2025, with an ultimate completion date of October 3, 2025, carries no set-aside designation. This award is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB program, a $499.999 billion vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products supporting medical supply needs across Department of Defense healthcare facilities worldwide. Xolair (omalizumab) is a monoclonal antibody used primarily in the treatment of moderate-to-severe allergic asthma and chronic idiopathic urticaria. As a DLA-supported supplier, DMS Pharmaceutical Group distributes branded and generic prescription drugs, biologics, and medical consumables to military and federal healthcare facilities nationwide. The company has demonstrated consistent success in securing federal pharmaceutical contracts, leveraging its woman-owned small business status to compete effectively in defense procurement markets while maintaining a robust portfolio of specialized medical product deliveries.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 9/12/25 |